BIOMAT Database Logo BIOMAT Database Logo

CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. 2020

Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Research Division, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan. kashimaknj@chugai-pharm.co.jp.

Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mutations (Del19/T790M/C797S or L858R/T790M/C797S) have been reported. Although allosteric EGFR TKIs (e.g., EAI-045) that potentially overcome L858R/T790M/C797S have been identified, there are no effective inhibitors against Del19/T790M/C797S. In this study, we identified CH7233163 as having the potential to overcome EGFR-Del19/T790M/C797S. CH7233163 showed potent antitumor activities against tumor with EGFR-Del19/T790M/C797S in vitro and in vivo In addition to EGFR-Del19/T790M/C797S, the characterization assays showed that CH7233163 more selectively inhibits various types of EGFR mutants (e.g., L858R/T790M/C797S, L858R/T790M, Del19/T790M, Del19, and L858R) over wild type. Furthermore, crystal structure analysis suggested that CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S that utilizes multiple interactions with the EGFR's αC-helix-in conformation to achieve potent inhibitory activity and mutant selectivity. Therefore, we conclude that CH7233163 is a potentially effective therapy for osimertinib-resistant patients, especially in cases of EGFR-Del19/T790M/C797S.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000178 Acrylamides Colorless, odorless crystals that are used extensively in research laboratories for the preparation of polyacrylamide gels for electrophoresis and in organic synthesis, and polymerization. Some of its polymers are used in sewage and wastewater treatment, permanent press fabrics, and as soil conditioning agents.
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.
December 2019, Chemical science,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation.
February 2022, ACS medicinal chemistry letters,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.
December 2023, European journal of medicinal chemistry,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
November 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
May 2024, Experimental & molecular medicine,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.
May 2023, ACS medicinal chemistry letters,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
November 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Structural pharmacological studies on EGFR T790M/C797S.
June 2017, Biochemical and biophysical research communications,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
September 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Kenji Kashima, and Hiroki Kawauchi, and Hiromi Tanimura, and Yukako Tachibana, and Takashi Chiba, and Takuya Torizawa, and Hiroshi Sakamoto
Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy.
August 2023, Quantitative imaging in medicine and surgery,
Copied contents to your clipboard!